Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 1
2009 1
2011 1
2012 1
2014 1
2015 2
2017 1
2018 4
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
Howe AYM, Rodrigo C, Cunningham EB, Douglas MW, Dietz J, Grebely J, Popping S, Sfalcin JA, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, Di Maio VC, Chulanov V, Pawlotsky JM, Harrigan PR, Ceccherini-Silberstein F, Garcia F; SHARED Collaborators. Howe AYM, et al. JHEP Rep. 2022 Feb 24;4(5):100462. doi: 10.1016/j.jhepr.2022.100462. eCollection 2022 May. JHEP Rep. 2022. PMID: 35434589 Free PMC article.
Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway.
Kjellin M, Kileng H, Akaberi D, Palanisamy N, Duberg AS, Danielsson A, Kristiansen MG, Nöjd J, Aleman S, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Kjellin M, et al. Among authors: lannergard a. Scand J Gastroenterol. 2019 Aug;54(8):1042-1050. doi: 10.1080/00365521.2019.1652846. Epub 2019 Aug 19. Scand J Gastroenterol. 2019. PMID: 31424972
Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
Kileng H, Kjellin M, Akaberi D, Bergfors A, Duberg AS, Wesslén L, Danielsson A, Gangsøy Kristiansen M, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Kileng H, et al. Among authors: lannergard a. Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1347-1353. doi: 10.1080/00365521.2018.1511824. Epub 2018 Nov 5. Scand J Gastroenterol. 2018. PMID: 30394152
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators. Wilcox MH, et al. N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615. N Engl J Med. 2017. PMID: 28121498 Free article. Clinical Trial.
Serum pentraxin 3 concentrations in neonates.
Lannergård A, Rosenström F, Normann E, Larsson A. Lannergård A, et al. Ups J Med Sci. 2014 Mar;119(1):62-4. doi: 10.3109/03009734.2013.878770. Epub 2014 Jan 17. Ups J Med Sci. 2014. PMID: 24438192 Free PMC article. No abstract available.
16 results